Norucholic acid for primary sclerosing cholangitis
Part of Digestive system clinical trials.
This study tests a new drug, norucholic acid, in people with primary sclerosing cholangitis (PSC), a liver disease. It is for people who were in an earlier trial of this drug and may help manage their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary sclerosing cholangitis (PSC).
- You took part in the previous NUC-5/PSC trial and either finished it or stopped early because the drug wasn't working.
- You did not stop the earlier trial due to side effects from the study drug.
- You do not have cirrhosis or a history of liver transplantation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.